Self-administered high-flow therapy for COPD and type 1 respiratory failure: benefit not proven

Self-administered high-flow therapy for COPD and type 1 respiratory failure: benefit not proven Due to a lack of meaningful study data, no benefit can be derived. As the legal requirements for a potential of the intervention are fulfilled, IQWiG formulated key points for two testing studies.